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Iowa
Board of Pharmacy
Rules Update
The Iowa Board of Pharmacy has recently revised many of its 
administrative rules. A summary is provided below. Please review 
the rules online at www.legis.iowa.gov/IowaLaw/AdminCode/
chapterDocs.aspx?agency=657 for additional information.
1. 657 IAC: Chapters 2, 3, 5, 8, 10, 12, 17, 24,  
and 30 – Reduction of Licensing and Registration 
Fees
Rules 2.3(1), 2.6, 2.9(4), 2.11, 2.11(1), 3.10(1), 5.9(1), 5.9(2), 
5.11(1), 8.35(4), 10.3, 10.3(2), 12.7(2), 17.3(2), 24.7(4), and 30.8 
Initial, renewal, and penalty fees are reduced by at least 10%. 
In addition, the Iowa Pharmacy Recovery Network surcharge will 
not be applied to pharmacists, technicians, or interns during 2013.
License Type Previous Fee/Revised Fee Reduction
Pharmacy License $150/$135 10%
Wholesaler License $300/$270 10%
Pharmacist License $220/$180 18%
Intern Registration $33/$30 9%
Tech Registration $55/$40 27%
Pharmacy Support 
Persons Registration $30/$25 16%
Controlled Substance 
Application Registration $100/$90 10%
Effective January 16, 2013.
2. 657 IAC: Chapter 2 – Pharmacist Licenses
Rule 2.12 Continuing education requirements
Pharmacists shall be required to register with the National As-
sociation of Boards of Pharmacy® CPE Monitor® service for the 
purpose of recording and maintaining evidence of continuing edu-
cation (CE) activities.
Rule 2.17 Continuing professional development portfolio
Pharmacists may fulfill CE requirements for license renewal or 
reactivation by submission of a continuing professional development 
portfolio that utilizes documented learning outcomes.  
The Board is offering a pilot program for 2013 renewals for those 
pharmacists who notify the Board by April 1, 2013. This will be 
available for up to 50 pharmacists.
Effective March 13, 2013.
3. 657 IAC: Chapter 6 – General Pharmacy Practice
Rule 6.2(14) Pharmacist in charge – Policies & Procedures
The duties of the pharmacist-in-charge (PIC) regarding written 
policies and procedures (P&P) are clarified. PIC shall ensure that 
all pharmacy personnel are familiar with P&Ps.
Effective January 16, 2013.
Rule 6.9(3) Transfer of prescription – Communication
Prescriptions may be transferred from one pharmacy to another 
via facsimile (pharmacist or intern must initiate the transfer).
The prescription transfer record shall contain certain required 
information.
Effective November 7, 2012.
4. 657 IAC: Chapter 7 – Hospital Pharmacy Practice
Rules 7.7 and 7.7(1) Verification by remote pharmacist
Remote pharmacist services may be provided when the pharmacy 
department is open to supplement on-site hospital pharmacy services. 
Such activities are intended to increase the availability of the hospital 
pharmacist for involvement in cognitive and patient care activities. 
Appropriate records shall be maintained.
Effective January 16, 2013.
Rule 7.11(2)“c” Outpatient services, drug administration in 
the outpatient setting
An outpatient medication order for administration of a Schedule 
II controlled substance (CS) may authorize the administration of an 
appropriate amount of the prescribed substance for a period not to 
exceed 90 days from the date ordered.
Effective September 12, 2012.
5. 657 IAC: Chapter 8 – Universal Practice 
Standards
Rule 8.5(4) Environment and Equipment Requirements – Re-
model or Relocation – Inspection 
Requirements for the remodeling or relocation of a pharmacy 
department are clarified, including Board notice (30 days prior) 
and inspection.
Effective January 16, 2013.
Rule 8.40 Pharmacy pilot or demonstration research projects
Procedures and application requirements are established. Projects 
shall not exceed 18 months in duration. Only projects that expand 
pharmaceutical care services and contribute to positive patient out-
comes will be considered.
Effective November 21, 2012. Continued on page 4
risk thereof,” and recommends completing an RCA for all sentinel events 
for health care organizations in which they accredit. It is anticipated that 
RCA for sentinel events may be required as part of an accreditation program 
for community/ambulatory pharmacies. 
RCA is a process for identifying the basic or causal factors that underlie 
variation in performance, including the occurrence or risk of occurrence 
of a sentinel event. RCA focuses primarily on systems and processes, 
not individual performance. Finding and identifying root causes during 
an investigation adds considerable value by pointing out significant, 
underlying, fundamental conditions that increase the risk of adverse 
consequences. These analyses can be of enormous value in capturing both 
the big-picture perspective and the details of the error. They facilitate system 
evaluation, analysis of need for corrective action, and tracking and trending. 
The RCA process starts by creating a team, holding a meeting, and 
stating the problem. The team gathers documentation (prescriptions, 
labels, computer reports, etc) and interviews staff involved in the error to 
determine the sequence of events. 
The RCA team will review the documentation and review the sequence 
of events and continue asking themselves “Why did this happen?” until 
they arrive at each root cause.
The team must assume that any problem is preventable and caused by 
weak or vulnerable systems rather than individual incompetence. Even in 
the case of a person making a mistake, the team must ask “Why do our 
systems allow these types of mistakes to happen so easily?” or “What 
factors set this person up to make this error?” 
The heart of the process is the analysis itself. Table 1 lists basic questions 
that should be answered during RCA. 
Table 1. Basic Questions to Answer During RCA
1. What happened?
2. What normally happens?
3. What do policies/procedures require?
4. Why did it happen?
5. How was the organization managing the risk before the  
    event?
It is important to answer “What normally happens?”(Question 2, in 
the above table). The difference between “What normally happens?” 
and “What do the policies and procedures require?” (Question 3) helps 
determine the reliability of processes and how often staff cut corners to 
get the work done.
RCA also includes a method to measure the effectiveness of these 
strategies over time. Targeting corrective measures at the identified root 
causes is the best way to ensure that similar problems do not occur in the 
future. 
USP Releases Universal Standards for Prescription 
Labels 
New United States Pharmacopeial Convention (USP) standards for a 
universal approach to the format, appearance, content, and instructions for 
medicines in containers dispensed by pharmacists have been released. “Wide 
variability in prescription container labels exists today across individual 
prescriptions, pharmacies, retail chains and states. The USP standards 
provide specific direction on how to organize labels in a ‘patient-centered’ 
manner that best reflects how most patients seek out and understand 
medication instructions,” as explained in a USP press release. Lack of 
universal standards for medication labeling can contribute to patients 
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NIH Database Provides Information on Drugs 
Associated With Liver Injury 
The National Institutes of Health (NIH) has launched a free searchable 
database with information on prescription and over-the-counter (OTC) 
drugs, herbals, and dietary supplements associated with liver injury. The 
LiverTox database, www.livertox.nih.gov, is a free resource for health 
care providers and researchers studying liver injury associated with these 
products. The database provides up-to-date, accurate, and easily accessed 
information on the diagnosis, cause, frequency, patterns, and management 
of liver injury attributable to prescription and nonprescription medications, 
herbals, and dietary supplements. The database currently contains 
information on 700 medications, and 300 more will be added. 
Coalition Urges Consumers to ‘Double Check, Don’t 
Double Up’ on Acetaminophen 
With the start of cold and flu season in October 2012, the Acetaminophen 
Awareness Coalition began urging consumers to double check their 
medicine labels to make sure they do not double up on medicines 
containing acetaminophen. The coalition’s “Double Check, Don’t 
Double Up” message is aimed to reach the more than 50 million 
Americans who use acetaminophen every week, encouraging them to 
take three simple steps to avoid acetaminophen overdose: (1) know if 
your medicine contains acetaminophen; (2) never take two medicines 
with acetaminophen at the same time; and (3) always read your medicine 
label. The coalition also wants to educate consumers that taking more 
acetaminophen than directed is an overdose and can lead to liver damage. 
Health care providers can join the effort by educating patients about safe 
use of acetaminophen, and can refer patients to the KnowYourDose.org 
Web site for more information. The Acetaminophen Awareness Coalition 
is made up of a diverse group of organizations representing health care 
providers and consumers who have joined forces through the Know Your 
Dose campaign to inform consumers about safe acetaminophen use and 
preventing liver damage that can result from unintentional overdose.  
Root Cause Analysis
This column was prepared by the Institute 
for Safe Medication Practices (ISMP). ISMP 
is an independent nonprofit agency that 
analyzes medication errors, near misses, and 
potentially hazardous conditions as reported 
by pharmacists and other practitioners. ISMP then makes appropriate 
contacts with companies and regulators, gathers expert opinion about 
prevention measures, and publishes its recommendations. To read about 
the risk reduction strategies that you can put into practice today, subscribe 
to ISMP Medication Safety Alert!® Community/Ambulatory Care Edition 
by visiting www.ismp.org. ISMP is a federally certified patient safety 
organization, providing legal protection and confidentiality for submitted 
patient safety data and error reports. ISMP is also an FDA MedWatch 
partner. Call 1-800/FAIL-SAF(E) to report medication errors to the ISMP 
Medication Errors Reporting Program or report online at www.ismp.org. 
ISMP address: 200 Lakeside Dr, Suite 200, Horsham, PA 19044. Phone: 
215/947-7797. E-mail: ismpinfo@ismp.org.
To assist pharmacists in the process of minimizing the occurrence of 
medication errors, many state boards of pharmacy are contemplating or 
already requiring community pharmacies to have a continuous quality 
improvement program in place. Many of these state’s regulations include 
the requirement of root cause analysis (RCA) in the case of sentinel 
events. The Joint Commission defines a sentinel event as an “unexpected 
occurrence involving death or serious physical or psychological injury or 
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misunderstanding dosage instructions and can lead to medication errors. 
Elements of the new USP standards, contained in General Chapter <17> 
Prescription Container Labeling, of the USP and the National Formulary, 
include:
 ♦ Emphasizing instructions and other information important to 
patients
 ♦ Improving readability
 ♦ Giving explicit instructions
 ♦ Including purpose for use
 ♦ Addressing limited English proficiency
 ♦ Addressing visual impairment
Descriptions of each standard including examples, as well as more 
information about the development of the standards, are provided in 
a USP press release, available at http://us.vocuspr.com/Newsroom/
ViewAttachment.aspx?SiteName=USPharm&Entity=PRAsset&Attach
mentType=F&EntityID=109587&AttachmentID=5dc9eb96-5706-4e61-
b0fa-ce9673fb3010. 
Enforcement of the standards will be the decision of individual state 
boards of pharmacy, which may choose to adopt it into their regulations, 
notes USP. The National Association of Boards of Pharmacy® (NABP®) 
member boards adopted Resolution 108-1-12 at the NABP 108th Annual 
Meeting stating that the Association should support state boards of 
pharmacy in efforts to require a standardized prescription label. NABP 
also convened a task force on this issue in December 2008. The resolution 
and the Report of the NABP Task Force on Uniform Prescription Labeling 
Requirements are available in the Members section of the NABP Web site.
New Law Increases Penalties on Medical Cargo 
Theft 
New legislation signed into law by President Obama on October 5, 
2012, increases penalties for medical product cargo theft, a significant 
problem that threatens patient safety when these stolen products are 
reintroduced into the legitimate supply chain. The Strengthening and 
Focusing Enforcement to Deter Organized Stealing and Enhance Safety 
Act of 2012 (SAFE DOSES Act) prohibits theft of medical products as 
well as trafficking, buying, selling, or distributing illegally obtained pre-
retail medical products. The law “prescribes criminal and civil penalties 
for violations, including a civil penalty of up to the greater of 3 times the 
economic loss attributable to the violation or $1 million.” According to 
the Coalition for Patient Safety and Medicine Integrity, “current federal 
criminal laws do not distinguish between stealing a load of insulin and 
stealing a truck full of paper clips.” By increasing the penalties for medical 
theft, the SAFE DOSES Act should help deter such theft. The text of the 
new law is available for download from the Government Printing Office 
Web site at www.gpo.gov/fdsys/pkg/BILLS-112hr4223enr/pdf/BILLS-
112hr4223enr.pdf.
NABP Implements Action Plan to Assist States in 
Regulating Compounding Pharmacies
Supporting state board of pharmacy efforts to enforce compounding 
regulations, NABP is implementing a four-part action plan centered 
around inspection of nonresident compounding pharmacies and creating 
an information-sharing network of regulatory details on such pharmacies. 
Focusing on inspections of nonresident compounding pharmacies and 
sharing this data among boards of pharmacy nationwide was determined 
by NABP and its member state boards of pharmacy to be key to preventing 
future tragedies like the current meningitis outbreak. 
NABP developed the action plan at a November 2012 meeting of board 
of pharmacy executive directors where the attendees expressed a strong 
commitment to correcting system failures that allowed the meningitis 
outbreak to occur, and implementation began quickly thereafter. The Iowa 
Board of Pharmacy recently requested NABP to develop an inspection 
program for entities that are licensed by the state as nonresident pharmacies 
and dispensing compounded drugs in Iowa. Those in attendance expressed 
their support of this inspection initiative, which became a cornerstone of 
the four-part action plan.
In the first part of its action plan, NABP shared the list of nonresident 
compounding pharmacies provided by the Iowa Board with other NABP 
member boards of pharmacy and began coordinating the collection of 
information on these pharmacies. The boards’ collaboration on this data 
helped NABP identify the initial pharmacies to inspect. NABP believes that 
the list provided by Iowa represents a significant number of nonresident 
pharmacies dispensing compounded drugs across the country.
Implementing the inspection program is the second part of the action 
plan and is currently underway. Initial results will reveal whether the select-
ed pharmacies are compounding pursuant to a prescription in compliance 
with state regulations, or instead are engaging in manufacturing. Entities 
that refuse inspection may be subject to disciplinary action by the Iowa 
Board and such actions will be shared with all of NABP’s member boards. 
The third part of the action plan includes NABP collecting and main-
taining data on the compounding pharmacies identified by the Iowa Board 
and by other boards of pharmacy. Initial data collected from the boards 
and the inspection reports will be stored in an NABP Pharmacy e-Profile, 
allowing the Association to disseminate pertinent public information 
among state boards. Ultimately, states will be able to submit inspection 
reports and other related information to NABP for inclusion in pharmacies’ 
e-Profiles. The network will be made available at no cost to boards for use 
in making licensure and registration determinations for pharmacies, and 
may also help to identify pharmacies whose operations are more akin to 
manufacturing than compounding.
As the final part of the action plan, NABP plans to schedule immediate 
and ongoing training of board of pharmacy inspectors and compliance of-
ficers via Webinar and field training opportunities. NABP will also continue 
cooperative efforts with Food and Drug Administration and legislators to 
address the regulatory quagmire that exists when traditional compounding 
is exceeded and manufacturing may be occurring. 
Pharmacists & Technicians: 
Don't Miss Out on Valuable CPE Credit. 
Set Up Your NABP e-Profile and  
Register for CPE Monitor Today!
CPE Monitor™ integration is underway. Most Accreditation Council 
for Pharmacy Education (ACPE)-accredited providers should now be 
requiring you to submit your NABP e-Profile ID, assigned when you 
set up your NABP e-Profile, along with your date of birth (MMDD), in 
order to obtain continuing pharmacy education (CPE) credit for any 
ACPE-accredited activity.
Visit www.MyCPEmonitor.net to set up your e-Profile, obtain your 
e-profile ID, and register for CPE Monitor and avoid possible delays in 
your CPE reporting.
CPE Monitor is a national collaborative service from  
NABP, ACPE, and ACPE providers that will allow licensees  
to track their completed CPE credit electronically.
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6. 657 IAC: Chapter 11 – Drugs in Emergency 
Medical Services Programs
Rules 11.4(2), 11.11(1), and 11.20(1)
The definition of “drug” is clarified to not include non-medicated 
intravenous solutions such as saline.
Required records shall be maintained for inspection. The require-
ments for monthly inspections of drug supplies maintained at the 
primary emergency medical services program site are clarified. The 
requirements for record keeping following the administration of a 
CS are clarified.
Effective November 7, 2012.
7. 657 IAC: Chapter 24 – Pharmacy Internet Sites
Rule 24.3(3) Iowa PMP
Out-of-state and Internet pharmacies that provide CS to patients 
in Iowa shall report such information to the Iowa Prescription Moni-
toring Program (PMP).
Effective January 1, 2013.
8. 657 IAC: Chapter 37 – Iowa Prescription 
Monitoring Program
Rules 37.2 and 37.4(1)
“Health care professional” and “practitioner’s agent” are defined.
A practitioner may authorize up to three health care professionals 
to act as the practitioner’s agent for the purpose of requesting PMP 
information. Agents shall register with the PMP program and may 
not delegate program access to other individuals.
Effective July 1, 2012.
Rules 37.2 and 37.3(3)
The definition of “dispenser” is expanded to include pharmacies 
located outside of Iowa that hold an Iowa nonresident pharmacy 
license and that dispense CS to patients in Iowa.
Reporting frequency for pharmacies is increased from twice a 
month to at least weekly.
Effective January 1, 2013.
9. 657 IAC: Chapter 100 – Iowa Real-Time 
Electronic Pseudoephedrine Tracking System
Rule 100.3(4)
Sales transactions shall be maintained when the electronic system 
is unavailable. Such transactions shall be entered within 72 hours 
of when the electronic system is again available. The definition of 
“law enforcement officer” is expanded to include probation and 
parole officers.
Effective July 18, 2012.
A Reminder Regarding Online Medical and 
Prescription Services
The Board has become aware that new online medical services 
are being offered to patients by various health care providers. Iowa 
pharmacists should review the following rule, which applies to these 
types of practices:
657 IAC 8.19(5) Legitimate purpose. The pharmacist shall 
ensure that the prescription drug or medication order, regard-
less of the means of transmission, has been issued for a legiti-
mate medical purpose by an authorized practitioner acting in 
the usual course of the practitioner’s professional practice. A 
pharmacist shall not dispense a prescription drug if the phar-
macist knows or should have known that the prescription was 
issued solely on the basis of an Internet-based questionnaire, an 
Internet-based consultation, or a telephonic consultation and 
without a valid preexisting patient-practitioner relationship. 
Compounding Hydroxyprogesterone 
Caproate
On June 15, 2012, Food and Drug Administration (FDA) issued 
a statement indicating it will apply its normal enforcement policies 
for pharmacies compounding hydroxyprogesterone caproate. In line 
with FDA’s statement, licensees are reminded that 20 CSR 2220-
2.200(9) provides: 
Compounding of drug products that are commercially available 
in the marketplace or that are essentially copies of commer-
cially available Federal [Food and] Drug Administration (FDA) 
approved drug products is prohibited. There shall be sufficient 
documentation within the prescription record of the pharmacy 
of the specific medical need for a particular variation of a com-
mercially available compound. Accordingly, licensees must 
have sufficient documentation of a specific medical need prior 
to compounding hydroxyprogesterone caproate in the future.
Continued from page 1
• Indicate on prescription with “for seizures” or “for epilepsy”
• Write or indicate Dispense As Written or “DAW”
• Talk to your Patients about the importance of their      
   medication and how all pills may not be the same
• Note Patient’s medical condition in the pharmacy profile
• Maintain the Patient on the same manufacturer when possible
• Notify the Patient and Provider when a manufacturer change  
   may need to be made
• Notify your Provider of unusual seizure activity or breakthrough seizures
• Know the manufacturers of your medications. If your medications look different,  
   talk to your Pharmacist before taking it
• Don’t wait until you are out of your medication to pick up or request a refill,
 this allows the necessary time for your Pharmacist to ensure your
 medications are in stock
* Information came from http://www.NoMoreSeizures.org
For task force information or to print more flyers please go to http://www.idph.state.ia.us/CDPM/ETFI.aspx
For questions or additional information please email efiowa@efncil.org
Brought to you by the Iowa Epilepsy Treatment & Education Task Force working together 
Patients, Providers and Pharmacists towards the goal of no more seizures. 
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Working Together Patients, Providers and Pharmacists
did You Know?
When treating seizures it is vital that the patient 
receives the same medication from the same 
manufacturer monthly in order to maintain the 
expected level of seizure control and side effects.*
